 

UUID: EA8A9A91- 7A83- 4EC9- BTAB- -0C3398[i‘1FeDl4a ZZELD 5
TCGA- XX- -A899- 61A- PR 0

llllllllll|lllllllllllllllllllllllllllllllllllllllllRllllclllllllleel W
ll|||||||||llllll||||llllll|lll|llllllllllllllllllllllllllll NO 5 / [yr/“X 52015
lllllllllllllllllllllllllllll||||l|||||ll|||||||||||||l|||||
5 {1 CE WN;5 £50 9
Research Gross Description ®P§gzwﬂb out L1299x70 505'
year old female multifocal breast cancer
1 I
Research Dx 9&5 I Lu! 3
Procedure: Total mastectomy (including nipple and skin)
Lymph node sampling: Sentinel lymph node and axillary dissection
Specimen laterality: Right
Tumor site: Multifocai, lower outer quadrant (majority of tumors) and lower inner quadrant
Tumor size: 2 x 1. 5 x 1.3 cm (largest tumor) 0;
Histopathologic type: Lobuiar with foci of Sig-Let r_i__ng morphology 0 " ”0' 4"? 31'1“
Histopathologic grade (Nottingham): 2
Mitotic count. 2 mitoses/10 hpf (low proliferative rate.)
Tumor focality: Multiple foci of invasive carcinoma
Pathologic tumor stage: pT1c: Tumor greater than 1 cm but less than or equal to 2 cm in greatest
dimension
Margin status: See below
Distance of carcinoma from margins:
Anterior: 0.35 mm (microscopic focus)
Posterior: 8 mm
All other margins greater than 1 cm
Associated in situ carcinoma: Yes
Type: LCIS
Extensive (>25% of total tumor): No
Separate (extra-tumoral) foci away from main lesion: Yes
Peritumoral angiolymphatic invasion: Not identified
Dermal angiolymphatic invasion: Not identified
Hormone receptors by properly controlled immunohistochemistry performed on previous core
biopsy
Estrogen receptor: Positive
Progesterone receptor: Positive
HER- 2Ineu (ERBBZ): Negative
Pathologic lymph node stage: pN2a: Metastasis' In 4- 9 axillary lymph nodes (at least one tumor
deposit greater than 2.0 mm)
Number of nodes positive for metastasis/total number nodes sampled. 5/22
Maximum diameter of largest lymph node metastasis: 1 cm
Extranodai extension by tumor. Present, focal

Distant metastasis: pM: Not applicable
Additional pathologic findings: Fibrocystic changes

I
I
ll

AJCC Staging (7th Edition): pT1c(m) pN2a pM: Not applicable

Research QC
Tumor:

80% tumor nuclei
0% necrosis
20% normal

Normal:
100% breast

 

 

Specimen Process Time
Blood draw time:

Plasma frozen time:

Serum frozen time:

Buffy coat frozen time,

Cold ischemia start time:
Formalin ﬁxation start time:
Total cold ischemia time:
Formalin ﬁxation stopped time:
Total formalin ﬁxation time:

Specimen Weight

Normal

1-512 mg, 2-351 mg, 3-283 mg, 4-372 mg
Tumor

1-262 mg, 2-205 mg, 3-208 mg, 4-317 mg
Specimen Size

Plasma x 3

Serum x 2

Buffy coat x 1

Cryovials x 8
Normal x 4

Tumor x 4: 1-2 lesion site A., 3-4 lesion site B.

FFPE x 8
Normal x 4

Tumor x 4: 1-2 lesion site A., 3-4 lesion site B.

Study

Patient Consent
Yes

sir:
"PM Disaepanw

'rioi' Malignancy History

'11:!-

 

 

 

2{Study Subject II):

Page 1 of 1

TCGA Pathologic Diagnosis Discrepancy Form 4.05

{

§Person ID I N/Ai

EStudy/ Site: TCGA Breast Invasive Carcinoma — (Breast invasive Carcinoma) éjltge: N/A:

EEvent: PathDiscrepancy Date of Birth: 3

Enemies? . . is“: .. ,. . . . if

Tumor Identiﬁer Provided an Initial Case Provide the tumor identiﬁer documented on the initial case quality
Quality Control Form control form for this case.

Pathologic Diagnosis Provided lnﬁltrating Iobular Provide the diagnosis] histologic subtype(s) documented on the initial

on Initial Pathology Report carcinoma pathology report for this case. If the histology for this case is mixed, provide all
listed subtypes.

Histologic features of the sample provided for signet ring Provide the histologic features selected on the TCGA Case

TCGA, as reflected on the CQCF morphology Quality Control Form compieted for this case.

Discrepancy between Pathology Report and Case Quality Control Form

1
l

Provide the reason for the pathology report reports the presence Provide a reason describing why the diagnosis on
discrepancy between the pathology of signet ring morphology, however, the initial pathology report for this case is not
report and the TCGA Case Quaiity the topslide contains 0% signet ring. consistent with the diagnosis selected on the TCGA
Control Form Case Quality Control Form.

Name of TSS Reviewing Pathologist or Provide the name of the pathologist who reviewed this
Biorepository Director case for TCGA.

